Please login to the form below

Not currently logged in
Email:
Password:

Almirall earnings hit by generics

Spanish pharmaceutical firm Almirall has said price erosion and generic competition is responsible for a fall in earnings in its first half financial report

Spanish pharmaceutical company Almirall has reported an 18 per cent decline in first half pre-tax earnings to €11.2m, citing price erosion and generic competition.

Its net sales fell by 9 per cent to €426.8m in the six month period to June 30. The company said that there was a stronger growth in European sales, which rose by 3.3 per cent, while sales in Africa, America and Asia increased by 3 per cent.

Eduardo Sanchiz, Almirall chief executive, said: "The first half of the year reflects a material improvement in P&L trends versus the first quarter and we maintain solid financial position and steady free cash flow generation that provides strategic flexibility."

The company said that cost discipline and savings were a continued priority for 2011, but put guidance for the rest of the year on hold.

28th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics